A major new review of existing research indicates that paracetamol is safe to take during pregnancy and does not raise the risk of autism, ADHD, or developmental issues in children, according to experts. The findings, published in a Lancet journal, directly contradict claims made last year by former U.S. President Donald Trump, who stated that paracetamol "is no good" and advised pregnant women to avoid it.

The study's authors hope the rigorous review will end the debate over paracetamol's safety during pregnancy, reassuring pregnant women about its use. "Pregnant women should feel reassured" by the findings, the researchers stated, emphasizing the lack of evidence supporting a link between paracetamol use and developmental disorders.

Trump's earlier assertions, which were widely criticized by medical organizations worldwide, caused confusion and concern among both women and healthcare professionals. The former president and his administration had suggested a link between paracetamol, known as acetaminophen in the U.S., and autism in children if the painkiller was taken during pregnancy.

Despite the new review, U.S. health officials maintain that "many experts" have expressed concern regarding the use of paracetamol during pregnancy. This divergence in opinion highlights the complexities of interpreting medical research and the challenges of communicating scientific findings to the public.

The debate around paracetamol's safety underscores the importance of evidence-based decision-making in healthcare. Medical professionals rely on systematic reviews and meta-analyses, like the one published in The Lancet, to synthesize existing research and provide informed recommendations. These reviews use statistical methods to combine the results of multiple studies, increasing the reliability and generalizability of the findings.

The implications of this research extend beyond individual health decisions. Public health guidelines and recommendations are often based on such studies, influencing healthcare policy and resource allocation. The dissemination of accurate information about medication safety is crucial for promoting informed choices and preventing unnecessary anxiety among pregnant women.

Further research may continue to explore the nuances of medication use during pregnancy. However, this latest review provides strong evidence supporting the safety of paracetamol and aims to alleviate concerns stemming from unsubstantiated claims. The ongoing dialogue between researchers, healthcare providers, and policymakers will be essential for translating scientific findings into practical guidance for pregnant women and their families.